Full name
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD) (BLISSс-ILD)
NCT Number
NCT05878717
Geography
US
Non-US
Locations
Argentina, Australia, Belgium, Brazil, China, Denmark. Finland, France, Germany, Greece, Israel, Italy, Japan, Republic of Korea, Mexico, Spain, United Kingdom, United States
Primary Endpoints
Absolute change from baseline in Forced Vital Capacity (FVC) milliliter (mL) at Week 52
External Link
https://clinicaltrials.gov/study/NCT05878717
Order
0
Disease
Version
Phase
2/3
Status
Recruiting